Trial of VLTS-589 in Subjects With Intermittent Claudication

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2003

Study Completion Date

June 30, 2005

Conditions
Intermittent ClaudicationPeripheral Vascular Disease
Interventions
GENETIC

Plasmid based Gene Transfer product-VLTS-589

Trial Locations (20)

10011

St. Vincent's Hospital, New York

27715

Duke Clinical Research Institute, Durham

30342

American Cardiovascular Research Institute, Atlanta

32207

Jacksonville Heart Center, Jacksonville

34239

Heart Specialists of Sarasota Clinical Research Center, Sarasota

35211

Cardiology Pc, Birmingham

37232

Vanderbilt University Medical Center, Nashville

46260

The Care Group, Indianapolis

48109

University of Michigan Health Systems, Ann Arbor

55407

Minneapolis Heart Institution Foundation, Minneapolis

60612

Rush Presbyterian St. Luke's Medical Center, Chicago

62701

Prairie Heart Institution at St. John's Hospital, Springfield

70119

New Orleans Center for Clinical Research, New Orleans

73104

University of Oklahoma Health Science Center, Oklahoma City

77030

The Methodist Hospital, Houston

85016

Arizona Heart Institute, Phoenix

90210

Access Clinical Trials-Cardiovascular Research, Beverly Hills

98166

Daniel Gottleib, MD, Seattle

04210

Androscoggin Cardiology Associates, Auburn

03756

Dartmouth-Hitchcock Medical Center, Lebanon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Valentis

INDUSTRY

NCT00068133 - Trial of VLTS-589 in Subjects With Intermittent Claudication | Biotech Hunter | Biotech Hunter